Welcome to our dedicated page for Staar Surg SEC filings (Ticker: STAA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The STAAR Surgical Company (NASDAQ: STAA) SEC filings page on Stock Titan brings together the company’s official disclosures from the U.S. Securities and Exchange Commission. STAAR is a medical device manufacturer focused on ophthalmic surgery, and its filings provide detailed information on its implantable intraocular lens business, corporate actions, and governance.
Investors can review Current Reports on Form 8-K in which STAAR reports material events, such as the August 2025 Agreement and Plan of Merger with Alcon, subsequent amendments, the go-shop process, adjournments of special meetings of stockholders, and later communications about the failure to obtain shareholder approval and the intended termination of the merger agreement. Other 8-K filings describe litigation related to the merger proxy statement, preliminary and final financial results, and leadership changes, including the appointment of a Chief Financial Officer and the creation of a Capital Stewardship Committee of the Board.
Filings also confirm that STAAR’s common stock is listed on Nasdaq under the symbol STAA and document how the proposed merger, if completed, would have affected listing status and registration. By reading these documents, users can trace the evolution of STAAR’s strategic transaction with Alcon, the role of major shareholders in the process, and the company’s decision to remain a standalone, publicly traded entity after the merger was not approved.
On Stock Titan, STAAR’s SEC filings are updated as new documents are released on EDGAR. AI-powered tools summarize lengthy filings such as 8-Ks and related exhibits, helping users quickly identify key terms, conditions, and outcomes without reading every page. This makes it easier to track transaction terms, board and management changes, and other disclosures that shape the outlook for STAA within the ophthalmic medical device industry.
STAAR Surgical reported a difficult 2025, with full-year net sales of
Operating expenses in 2025 were
Management highlighted improved in-market demand and normalized inventories in China, strong early demand for the higher-priced EVO+ lens, and a manufacturing ramp in Switzerland designed to avoid US‑China tariff volatility. After shareholders rejected a proposed merger with Alcon in January 2026, STAAR appointed Warren Foust and Deborah Andrews as interim co‑CEOs and emphasized renewed focus on revenue growth, profit expansion and innovation as a standalone company.
STAAR Surgical Company reports a sharp downturn as its ICL-focused business faces macro and market headwinds. Net sales were $239.4 million for fiscal 2025, down 23.7% from 2024, and the company recorded a net loss of $80.4 million after a prior-year loss.
China remains critical, contributing about 32% of 2025 net sales, but weak consumer demand, elevated distributor inventories, and tariff concerns depressed volumes versus 2024. STAAR incurred $17.1 million of merger-related costs before stockholders voted down its proposed sale to Alcon and the merger agreement was terminated without any termination fee.
The company remains almost entirely concentrated in Implantable Collamer Lenses, having sold more than 4,000,000 ICLs worldwide and deriving approximately 100% of 2025 sales from these lenses. Finished goods inventory totaled $39.7 million, equal to 219 days’ inventory on hand, as STAAR builds buffers and dual manufacturing capacity in the U.S. and Switzerland.
STAAR ended 2025 with about 957 employees32.2%, well above medical device industry levels. Management highlights dependence on China, competitive pressure from laser vision correction and rival phakic lenses, and evolving regulatory regimes as key ongoing risks.
STAAR Surgical director Christopher Min Fang Wang filed an initial ownership report showing indirect beneficial ownership of 3,257,130 shares of common stock. The holdings consist of 2,575,061 shares owned by Yunqi Path Capital Master Fund and 682,069 shares owned by Yunqi China Special Investment A. Through his roles with the Yunqi entities, Mr. Wang may be deemed to beneficially own these shares, but he disclaims beneficial ownership except to the extent of his pecuniary interest.
STAAR Surgical Company reported that Chief Legal Officer and Corporate Secretary Nathaniel Sisitsky entered a letter agreement providing for his termination of employment, effective February 4, 2026, which will be treated as a termination by the company without cause.
Under the agreement, and consistent with his prior severance arrangement, he is eligible for 12 months of base salary and 12 months of reimbursed insurance premiums, subject to a general release. He will also receive his 2025 annual bonus on the same basis as executives who remain employed, plus a remaining cash recognition and retention award installment of $75,000.
STAAR Surgical also entered into a consulting agreement under which Sisitsky will provide legal transition services through March 13, 2026, or earlier if agreed, for fees of $8,000 per week and a potential $10,000 completion fee. Restricted stock units scheduled to vest in March 2026 vested as of his separation date, while all other unvested equity awards were forfeited.
STAAR Surgical granted restricted stock units to Interim Co-CEO and President & COO Warren Foust. On February 2, 2026, he received 20,787 RSUs, each representing one share of common stock upon vesting at a price of $0 per unit.
The RSUs will vest as to 100% of the shares on August 1, 2026, assuming the vesting conditions are met. Following this grant, Foust beneficially owns 20,787 derivative securities directly in the form of these RSUs.
STAAR Surgical reported an equity award to interim executive Deborah J. Andrews, who serves as Interim Co-CEO and CFO. On February 2, 2026, she received 20,787 restricted stock units (RSUs) at a price of $0. Each RSU represents the right to receive one share of common stock upon vesting.
The RSU grant was made in connection with her appointment as Interim Co-Chief Executive Officer. All 20,787 RSUs will vest 100% on August 1, 2026, if the vesting conditions are met, giving her direct beneficial ownership of the underlying shares upon settlement.
STAAR Surgical Company appointed Warren Foust and Deborah Andrews as Interim Co‑Chief Executive Officers effective February 1, 2026, following the previously announced departure of CEO Stephen C. Farrell. The Board has formed a search committee and begun a global search for a permanent Chief Executive Officer.
Foust, currently President and Chief Operating Officer, and Andrews, currently Chief Financial Officer, will retain their existing roles while serving as Interim Co‑CEOs. Each will receive restricted stock units with a grant date fair value of $375,000, scheduled to vest on August 1, 2026 or an earlier date under the grant terms.
The company entered into a letter agreement with Foust setting his Interim Co‑CEO term through the earlier of August 1, 2026 or public announcement of a new CEO and clarifying when his resignation or termination would trigger “Good Reason” treatment and enhanced vesting and severance benefits under his existing agreements.
STAAR Surgical director Richard T. LeBuhn filed an initial statement of beneficial ownership of securities. He reports beneficial ownership of 21,268 shares of common stock held directly. He also reports 18 shares held in three separate accounts for his daughters, over which he has voting and dispositive control. In addition, 844 shares are held by an irrevocable trust for his daughter; he is not the trustee, has no voting or dispositive power over those securities, and disclaims beneficial ownership except to the extent of his pecuniary interest. The filing notes that Mr. LeBuhn was appointed to the company’s Board of Directors on January 14, 2026.
STAAR Surgical and major shareholder Broadwood Partners entered a cooperation agreement that reshapes the company’s board and clarifies the Broadwood group’s status. Broadwood Partners and Broadwood Capital report beneficial ownership of 15,453,629 shares each, or about 31.1% of the 49,741,953 shares outstanding as of October 31, 2025. Neal C. Bradsher may be deemed to beneficially own 15,479,529 shares, also about 31.1% of the class.
The agreement leads to two directors resigning, three new directors being appointed (including Bradsher and Richard T. LeBuhn) and nominated for election at the 2026 annual meeting. Broadwood agrees not to request a special shareholder meeting, including to remove directors, until June 18, 2026, and both sides provide mutual releases and non‑disparagement commitments.
STAAR Surgical Co received an updated ownership filing from a group of investment entities connected to Yunqi and HS Group. The largest reported position is 3,257,130 shares of common stock, representing 6.5% of the class, beneficially owned by Yunqi Capital Limited, Yunqi Capital Cayman Limited, Christopher Min Fang Wang, and related entities. Other entities in the group, including Yunqi Path Capital Master Fund and Yunqi China Special Investment A, report additional share holdings, with Yunqi Path Capital Master Fund alone reporting 2,575,061 shares, or 5.2% of the class. The amendment also notes that on January 14, 2026, STAAR Surgical entered into a cooperation agreement with Broadwood Partners, L.P., under which Christopher Min Fang Wang was appointed to the company’s Board of Directors effective that same date.